Connect your AI

Dianthus Therapeutics DNTH Shares (Basic)

Shares (Basic) at other companies

Johnson & JohnsonJNJ

2.4B+0.1%

AmgenAMGN

540M+0.4%

Spyre Therapeutics, Inc.SYRE

78.5M+30.3%

Kymera TherapeuticsKYMR

97.5M+21.7%

Protagonist TherapeuticsPTGX

65.1M+3.4%

TG TherapeuticsTGTX

144.4M-1.5%

Other financials

Income statement

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

Market cap$4.51B+662%

Profitability

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Dianthus Therapeutics's shares (basic)?: Dianthus Therapeutics (DNTH) reported shares (basic) of 48M in Q1 2026.
How has Dianthus Therapeutics's shares (basic) changed year-over-year?: Dianthus Therapeutics's shares (basic) increased by 34.2% year-over-year, from 35.8M to 48M.
What is the long-term trend for Dianthus Therapeutics's shares (basic)?: Over 3 years (2021 to 2024), Dianthus Therapeutics's shares (basic) has grown at a -16.1% compound annual growth rate (CAGR), from 215.8M to 127.4M.
What does shares (basic) mean?: The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.